Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature emphasizes precision-guided perioperative and critical-care strategies. A validated three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) quantifies immune dysregulation and identifies patients who benefited from hydrocortisone in severe pneumonia/sepsis. A multicenter RCT shows intraoperative low-dose esketamine rapidly reduces early postoperative depression and anxiety without added neuropsychiatric harm, supporting perioperative mental-health interv
Summary
This week’s anesthesiology literature emphasizes precision-guided perioperative and critical-care strategies. A validated three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) quantifies immune dysregulation and identifies patients who benefited from hydrocortisone in severe pneumonia/sepsis. A multicenter RCT shows intraoperative low-dose esketamine rapidly reduces early postoperative depression and anxiety without added neuropsychiatric harm, supporting perioperative mental-health interventions. A comprehensive network meta-analysis in obstetric anesthesia favors norepinephrine/metaraminol (α-agonists with mild β-activity) over ephedrine for spinal-induced hypotension, informing vasopressor choice.
Selected Articles
1. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
A multicohort study derived and externally validated a parsimonious ML framework (three biomarkers: procalcitonin, soluble TREM-1, IL-6) that quantifies immune dysregulation (DIP/cDIP). Higher dysregulation associated with increased mortality and secondary infection; post-hoc reanalysis of a hydrocortisone RCT suggested survival benefit only in patients with severe dysregulation, supporting biomarker-guided immunomodulation.
Impact: Provides a validated, clinically implementable 3-biomarker tool that addresses heterogeneity in sepsis trials and enables precision immunomodulation—potentially practice-changing for steroid allocation.
Clinical Implications: Consider measuring PCT, sTREM-1, and IL-6 to stratify pneumonia/sepsis patients for immunomodulatory therapies and to design biomarker-stratified trials of corticosteroids or other agents.
Key Findings
- A 3-biomarker model (PCT, sTREM-1, IL-6) predicted immune dysregulation with DIP accuracy 91.2% and cDIP RMSE 0.056.
- Increased cDIP was independently associated with higher mortality (OR 1.26 per 10% increase) and secondary infections (OR 1.50 per 10% increase).
- Reanalysis of a hydrocortisone RCT showed survival benefit only in severely dysregulated patients (e.g., cDIP ≥0.63; OR 0.21).
2. Esketamine hydrochloride in the management of moderate-to-severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi-centre randomized, double-blind, placebo-controlled trial.
A multicenter double-blind RCT (n=130) found that intraoperative low-dose esketamine (0.2–0.3 mg/kg) significantly increased MADRS response and remission rates on postoperative days 1–3 and improved PHQ-9/HADS-A scores, without increasing neuropsychiatric adverse events within 30 days. Results support esketamine as a rapid perioperative intervention for depressive and anxiety symptoms in selected surgical patients.
Impact: First high-quality multicenter double-blind evidence that intraoperative low-dose esketamine produces rapid, clinically meaningful improvements in postoperative mood/anxiety without short-term safety penalties—opening a new perioperative therapeutic avenue.
Clinical Implications: In selected patients (e.g., repeated debridement), consider intraoperative low-dose esketamine as an adjunct to improve early postoperative mood/anxiety, with appropriate monitoring for ketamine-related effects and further follow-up.
Key Findings
- Esketamine increased MADRS response on POD1 (53.8% vs 26.2%, p=0.001) and improved remission rates across POD1–3.
- Improved HADS-A and PHQ-9 scores by POD3 versus placebo.
- No increase in neuropsychiatric adverse events within 30 days (assessed by YMRS, CADSS, BPRS).
3. Efficacy and safety of different vasopressor infusions on feto-maternal outcomes in normotensive patients undergoing caesarean delivery: a systematic review and network meta-analysis of randomised controlled trials.
This network meta-analysis of 55 RCTs (n=5,487) found that continuous infusions of α-agonists with mild β-activity (norepinephrine, metaraminol) and phenylephrine reduce spinal-induced maternal hypotension compared with no infusion, and that metaraminol/mephentermine better preserved umbilical acid–base status. Overall, agents with mild β-activity were favored over ephedrine, informing vasopressor choice in cesarean delivery.
Impact: Aggregates extensive RCT data to clarify vasopressor comparative effectiveness and neonatal acid–base outcomes, likely influencing guideline and bedside vasopressor selection for cesarean spinal anesthesia.
Clinical Implications: Prefer norepinephrine or metaraminol infusions over ephedrine for prophylaxis of spinal-induced hypotension in cesarean delivery, balancing maternal hemodynamics with neonatal acid–base preservation and anticipating different bradycardia risks.
Key Findings
- Four vasopressors (metaraminol, norepinephrine, phenylephrine, adrenaline) were superior to no infusion for preventing maternal hypotension.
- Mephentermine and metaraminol better preserved umbilical arterial and venous acid–base balance.
- Alpha-agonists with mild beta activity outperformed ephedrine for maternal hemodynamic stability.